Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., Duffield, E. L., Rukazenkov, Y., Speake, G., Jiang, H., ArVolume:
29
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/jco.2010.33.4235
Date:
July, 2011
File:
PDF, 241 KB
english, 2011